Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Current Deferred Revenue for 3 consecutive years, with $402000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 94.53% to $402000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $402000.0 through Dec 2025, down 94.53% year-over-year, with the annual reading at $402000.0 for FY2025, 94.23% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $402000.0 at Telix Pharmaceuticals, down from $7.4 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $7.4 million in Q4 2024, with the low at $402000.0 in Q4 2025.
  • Average Current Deferred Revenue over 3 years is $5.0 million, with a median of $7.2 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue grew 2.77% in 2024, then crashed 94.53% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $7.2 million in 2023, then increased by 2.77% to $7.4 million in 2024, then plummeted by 94.53% to $402000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $402000.0, $7.4 million, and $7.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.